| |
CAMBRIDGE, MA — September 14, 2004 –
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company
developing drugs based on sugar sequencing technology, announced today
that its Chairman and Chief Executive Officer, Alan Crane, will present
at the ThinkEquity Partners Growth Conference on Tuesday, September
21, 2004 at 3:00 pm Pacific Standard Time at the Omni Hotel, San Francisco,
CA.
A live webcast of the presentation will be available on the “Investors”
section of the Company’s website located at www.momentapharma.com.
A replay of the presentation will be posted on the Momenta website approximately
five minutes after the event and will be available through October 21,
2004.
About Momenta
Momenta Pharmaceuticals, Inc. is a biotechnology company specializing
in the sequencing and engineering of complex sugars for the development
of improved versions of existing drugs, the development of novel drugs
and the discovery of new biological processes. Momenta is also utilizing
its ability to sequence sugars to create technology-enabled generic
products. The Company’s most advanced product candidate is M-Enoxaparin,
a technology-enabled generic version of Lovenox®. Based on its understanding
of complex sugars, Momenta has created a diversified pipeline of novel
discovery and development candidates. Momenta was founded in 2001 and
is headquartered in Cambridge, MA.
To receive additional information about Momenta,
please visit the Company’s website at www.momentapharma.com, which
does not form a part of this press release.
Statements in this press release regarding future expectations, beliefs,
goals, plans or prospects constitute forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995.
Momenta’s actual results could differ materially from those stated
or implied in forward-looking statements due to a number of factors,
including those factors contained in Momenta’s final prospectus
dated June 21, 2004 filed with the Securities and Exchange Commission
in connection with Momenta’s initial public offering under the
section “Risk Factors,” as well as other documents that
may be filed by Momenta from time to time with the Securities and Exchange
Commission. Forward-looking statements include statements regarding
Momenta’s expectations, beliefs, intentions or strategies regarding
the future and can be identified by forward-looking words such as “anticipate”,
“believe”, “could”, “estimate”,
“expect”, “intend”, “may”, “should”,
“will”, and “would” or similar words. Momenta
assumes no obligations to update the information included in this press
release.
Our logo, trademarks, and service marks are the property of Momenta
Pharmaceuticals, Inc. All other trade names, trademarks, or service
marks are property of their respective owners and are not the property
of Momenta Pharmaceuticals, Inc.
Contact: Valerie Threlfall, Momenta Pharmaceuticals,
Inc., 617-395-5116
|
|
Press
Contact
press@momentapharma.com
Company
Fact Sheet
Technology
Fact Sheet
Regulatory
Fact Sheet
|
